Evaluation of Neoadjuvant Xaluritamig in Localized Prostate Cancer

← catalyst calendar

NCT06613100 · readout in 182 d

Sponsored by Amgen (industry) · AMGN — their whole pipeline →.

Phase

Phase 1

Status

Recruiting

Study type

Interventional

Design

Non randomized · None · Treatment

Enrollment

40estimated

Sites

Countries

Germany, United States

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2024-11-25

actual

When the study began enrolling

Primary completion

2027-02-17

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

2030-03-04

estimated

The whole study's end, after follow-up

First posted

2024-09-25

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-07-31

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

Prostate Cancer

Interventions

Drug: Xaluritamig — also filed as AMG 509
Drug: GnRH Antagonist

Primary outcomes

what the primary-completion date above is the date OF

Number of Participants who Experienced Treatment-emergent Adverse Events

measured Up to 45 months

Number of Participants who Experienced Treatment-related Adverse Events

measured Up to 28 months

Number of Participants who Received Radical Prostatectomy After Completing Xaluritamig Treatment

measured Up to 25 months

Number of Participants who Experienced Complications of Radical Prostatectomy According to Clavien-Dindo Classification

measured Up to 28 months

Permalink · AMGN's whole pipeline · Catalyst calendar · Every registered study · What changed